Articles dans des revues avec comité de lecture (396)
  1. 37. Franzoi, M. A., Ameye, L., Eiger, D., Piccart-Gebhart, M., Brandao, M., Pondé, N., Desmedt, C., Di Cosimo, S., Paesmans, M., Caparica Bitton, R., Kotecki, N., Lambertini, M., De Angelis, C., Awada, A., & de Azambuja, E. (2020). Corrigendum to “Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials”. Annals of oncology, 31(10), 1423. doi:10.1016/j.annonc.2020.07.018
  2. 38. Onesti, C. E., Rugo, H. H., Generali, D., Peeters, M., Zaman, K., Wildiers, H., Harbeck, N., Martin, M., Cristofanilli, M., Cortes, J., Tjan-Heijnen, V. C. G., Hurvitz, S., Berchem, G., Tagliamento, M., Campone, M., Bartsch, R., De Placido, S., Puglisi, F., Rottey, S., Müller, V., Ruhstaller, T., Machiels, J. P., Conte, P. F., Awada, A., & Jerusalem, G. (2020). Oncological care organisation during COVID-19 outbreak. ESMO Open, 5(4), e000853. doi:10.1136/esmoopen-2020-000853
  3. 39. Cho, B. C., Daste, A., Ravaud, A., Salas, S., Isambert, N., McClay, E., Awada, A., Borel, C., Ojalvo, L., Helwig, C., Rolfe, A. P., Gulley, J., & Penel, N. (2020). Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: Results from a phase i cohort. Journal for ImmunoTherapy of Cancer, 8(2), jitc-2020-000664. doi:10.1136/jitc-2020-000664
  4. 40. Engelman, D., Moreau, M., Lepida, A., Zaouak, Y., Paesmans, M., & Awada, A. (2020). Metastatic breast cancer and pseudocirrhosis: an unknown clinical entity. ESMO Open, 5(3). doi:10.1136/esmoopen-2020-000695
  5. 41. Perez-Gracia, J. L., Awada, A., Calvo, E., Amaral, T., Arkenau, H. T., Gruenwald, V., Bodoky, G., Lolkema, M. M., Di Nicola, M., Penel, N., Vera, R., Sanmamed, M. F., & Douillard, J.-Y. (2020). ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy. ESMO Open, 5(3), e000662. doi:10.1136/esmoopen-2019-000662
  6. 42. Krayem, M., Aftimos, P., Najem, A., van den Hooven, T., van den Berg, A., Hovestad-Bijl, L., de Wijn, R., Hilhorst, R., Ruijtenbeek, R., Sabbah, M., Kerger, J., Awada, A., Journé, F., & Ghanem, G. E. (2020). Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. Cancers (Basel), 12(2). doi:10.3390/cancers12020512
  7. 43. Caparica Bitton, R., Richard, F., Brandao, M., Awada, A., Sotiriou, C., & de Azambuja, E. (2020). Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer. Clinical breast cancer. doi:10.1016/j.clbc.2020.01.007
  8. 44. van Bussel, M., Awada, A., de Jonge, M. M., Mau-Sørensen, M., Nielsen, D. L., Schöffski, P., Verheul, H. M. W., Sarholz, B., Berghoff, K., El Bawab, S., Kuipers, M., Damstrup, L., Diaz-Padilla, I., & Schellens, J. J. (2020). A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours. British Journal of Cancer. doi:10.1038/s41416-020-01151-6
  9. 45. Johnston, S. R. D. S., Martin, M., Di Leo, A., Im, S. –., Awada, A., Forrester, T., Frenzel, M., Hardebeck, M. C., Cox, J., Barriga, S., Toi, M., Iwata, H., & Goetz, M. M. (2019). MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ breast cancer, 5(1), 5. doi:10.1038/s41523-018-0097-z
  10. 46. Jones, R. L., Ratain, M. M., O'Dwyer, P. P., Siu, L. L., Jassem, J., Medioni, J., DeJonge, M., Rudin, C., Sawyer, M. M., Khayat, D., Awada, A., de Vos-Geelen, J. J., Evans, T. R. J., Obel, J., Brockstein, B., DeGreve, J., Baurain, J.-F., Maki, R., D'Adamo, D., Dickson, M., Undevia, S., Geary, D., Janisch, L., Bedard, P. L., Abdul Razak, A. R., Kristeleit, R., Vitfell-Rasmussen, J., Walters, I., Kaye, S. S., & Schwartz, G. (2019). Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. European journal of cancer, 120, 132-139. doi:10.1016/j.ejca.2019.07.024
  11. 47. Krayem, M., Sabbah, M., Najem, A., Wouters, A., Lardon, F., Simon, S., Sales, F., Journé, F., Awada, A., Ghanem, G. E., & Van Gestel, D. (2019). The benefit of reactivating p53 under MAPK inhibition on the efficacy of radiotherapy in melanoma. Cancers (Basel), 11(8), 1093. doi:10.3390/cancers11081093
  12. 48. Marcoux, D., Ignatiadis, M., Paesmans, M., & Awada, A. (2019). Cancer du sein avec métastase inhabituelle au niveau vésical : Rapport de cas et revue systématique de la littérature. Revue médicale de Bruxelles, 40(3), 148-159. doi:10.30637/2019.18-077
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
    37     38 39 Suivant >>